US2010197646A1PendingUtilityA1

Solvent-based sterilisation of pharmaceuticals

50
Assignee: RESOLUTION CHEMICALS LTDPriority: Feb 19, 2002Filed: Apr 13, 2010Published: Aug 5, 2010
Est. expiryFeb 19, 2022(expired)· nominal 20-yr term from priority
A61K 9/14Y10T428/2982A61K 9/0078A61P 11/06A61L 2/022A61L 2/18A61L 2/02A61L 2103/05
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A sterile composition of a pharmaceutical compound is prepared by combining solvent with a non-sterile pharmaceutical compound to form a solution and filtering to yield a sterile pharmaceutical compound, optionally removing all or part of the solvent, and under sterile conditions combining the compound with a pharmaceutically acceptable carrier.

Claims

exact text as granted — not AI-modified
1 - 76 . (canceled) 
   
   
       77 . A method for preparing sterile budesonide comprising:
 (i) dissolving non-sterile budesonide in a solvent to form a non-sterile budesonide solution;   (ii) filtering the non-sterile budesonide solution with a sterile filter to produce a sterile budesonide solution; and   (iii) removing the solvent from the sterile budesonide solution to produce a sterile budesonide powder.   
   
   
       78 . The method as defined in  claim 77  wherein the sterile filter has a pore size of 0.2 μm or less. 
   
   
       79 . The method of  claim 77  further comprising the step of reducing the particle size of the sterile budesonide powder to a mass mean diameter of less than 10 μm. 
   
   
       80 . The method of  claim 79  wherein the particle size of the sterile budesonide powder is reduced to a mass mean diameter of 1-5μm. 
   
   
       81 . The method of  claim 80  wherein the particle size of the sterile budesonide powder is reduced to a mass mean diameter of 2-3μm. 
   
   
       82 . The method of  claim 77  wherein the steps of the method are conducted under low oxygen conditions. 
   
   
       83 . The method of  claim 77  wherein the steps of the method are conducted under vacuum conditions. 
   
   
       84 . The method of  claim 77  wherein the steps of the method are conducted under nitrogen conditions. 
   
   
       85 . The method of  claim 77  wherein the steps of the method are protected from light. 
   
   
       86 . The method of  claim 77  further comprising the step of packaging the sterile budesonide powder. 
   
   
       87 . The method of  claim 86  wherein the step of packaging the sterile budesonide powder is performed under sterile conditions. 
   
   
       88 . The method of  claim 77  wherein step (i) is conducted at room temperature. 
   
   
       89 . The method of  claim 77  further comprising the step of heating the solvent to 30-50° C. prior to dissolving the non-sterile budesonide. 
   
   
       90 . The method of  claim 77  wherein the solvent is removed under reduced pressure. 
   
   
       91 . The method of  claim 77  wherein the solvent is removed under vacuum conditions. 
   
   
       92 . The method of  claim 77  wherein the solvent is removed at a temperature of 40° C. or less. 
   
   
       93 . The method of  claim 77  further comprising the step of combining the sterile budesonide powder with a pharmaceutically acceptable carrier. 
   
   
       94 . The method of  claim 93  wherein the pharmaceutically acceptable carrier is sterile water. 
   
   
       95 . The method of  claim 77  wherein the solvent is a Class 2 solvent selected from the group consisting of acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethane, dichloromethane, 1,2-dimethoxyethane, 1,4-dioxane, 2-ethoxyethanol, ethyleneglycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, tetrahydrofuran, toluene, 1,2-trichloroethene and xylene. 
   
   
       96 . The method of  claim 77  wherein the solvent is a Class 3 solvent selected from the group consisting of acetone, anisole, 1-butanol, 2-butanol, butyl acetate, tert-butylmethyl ether, cumene, ethanol, ethyl acetate, ethyl ether, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1-butanol, methylethyl ketone, methylisobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 2-pentanol, 2-propanol, and propyl acetate. 
   
   
       97 . The method of  claim 77  wherein the solvent comprises an alcohol. 
   
   
       98 . The method of  claim 97  wherein the alcohol is ethyl alcohol, methyl alcohol or isopropyl alcohol.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.